Dr. Bendell on a Study of Onartuzumab Plus Bevacizumab for mCRC
In Partnership With:
Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).
Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).
The c-MET receptor pathway has been the subject of a lot of recent research, Bendell says. It has been observed that high levels of the c-MET receptor seem to be associated with poor prognosis across multiple tumor types.
A randomized, double-blind, placebo-controlled phase II study will evaluate onartuzumab in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated mCRC. It is hypothesized that the anti-VEGF abilities of bevacizumab will be synergistic with the anti-MET abilities of onartuzumab.
